Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The combined entity will have 12 hospitals with 3,666 beds
It plans to double its network to 50 centres across India in the next three years
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
